Michael J. Welsh Net Worth

The estimated Net Worth of Michael J. Welsh is at least 22.7 千$ dollars as of 16 March 2016. Michael Welsh owns over 40 units of Cancer Genetics stock worth over 22,730$ and over the last 10 years Michael sold CGIX stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Welsh CGIX stock SEC Form 4 insiders trading

Michael has made over 2 trades of the Cancer Genetics stock since 2016, according to the Form 4 filled with the SEC. Most recently Michael bought 40 units of CGIX stock worth 97$ on 16 March 2016.

The largest trade Michael's ever made was buying 40 units of Cancer Genetics stock on 16 March 2016 worth over 97$. On average, Michael trades about 13 units every 0 days since 2015. As of 16 March 2016 Michael still owns at least 5,040 units of Cancer Genetics stock.

You can see the complete history of Michael Welsh stock trades at the bottom of the page.

What's Michael Welsh's mailing address?

Michael's mailing address filed with the SEC is 201 NJ-17, Rutherford, NJ 07070, USA.

Insiders trading at Cancer Genetics

Over the last 12 years, insiders at Cancer Genetics have traded over 1,720,897$ worth of Cancer Genetics stock and bought 3,891,559 units worth 4,573,241$ . The most active insiders traders include John Pappajohn、Tommy G Thompson、John A Roberts. On average, Cancer Genetics executives and independent directors trade stock every 35 days with the average trade being worth of 340,207$. The most recent stock trade was executed by John A Roberts on 31 January 2019, trading 185,436 units of CGIX stock currently worth 42,650$.

What does Cancer Genetics do?

Complete history of Michael Welsh stock trades at Cancer Genetics

Cancer Genetics executives and stock owners

Cancer Genetics executives and other stock owners filed with the SEC include:

• Jane Houldsworth,
  Vice President - Research & Development
• Franklyn Prendergast,
  Independent Director
• Howard McLeod,
  Independent Director
• Edmund Cannon,
  Independent Director
• Thomas Widmann,
  Director
• Geoffrey Harris,
  Director
• John Roberts,
  President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer
• John Pappajohn,
  Non-Executive Chairman of the Board
• Panna Sharma,
  Chief Executive Officer
• Raju S.K. Chaganti,
  Director
• Michael J. Welsh,
  Director
• Edward J Sitar,
  Chief Financial Officer
• Igor Gitelman,
  Chief Accounting Officer
• Michael Brian Mc Cartney,
  Chief Commercial Officer
• Michael Glenn Miles,
  Chief Financial Officer
• Ralf Brandt,
  President, Discovery Services
• Rita Shaknovich,
  VP of Hematopathology Services
• Paul Rothman,
  Director
• Keith L Brownlie,
  Director
• Andrew L Pecora,
  Director
• Tommy G Thompson,
  Director
• Steven Hepburn,
  VP of Biopharma Marketing